Andrew Loblaw, Prostate Cancer researcher at Sunnybrook Health Sciences Centre, shared a post on X:
“Dr Goni Ramirez presents 20y data propensity-based analysis of LDR v HDR boost.
N=546 matched, both CT planned.
LDR = HDR for bDFS, MFS, CSS.
But LDR > HDR for late GU G3+ toxicity (20% at 10y!).
Maybe real-time HDR and IO LDR planning will risk?”
Stay tuned to OncoDaily for continued coverage and updates from ESTRO25.
